Thank you for submitting your manuscript for consideration by the EMBO Journal. Please let me first apologise for the delay in getting back to you with a decision on your manuscript: this was due to the late return of one of the referees' reports. However, we do now have all three reports, which are enclosed below. As you will see, all three referees express interest in your work, particularly in that you have been able to resolve the transmembrane domains of the E1/E2 proteins in your structure. Referees 1 and 3 are supportive of publication in the EMBO Journal pending satisfactory revision, while referee 2 suggests that the study would be better focussed on the analysis of the TM domains, and would be more appropriate for our sister journal, EMBO Reports. However, given the positive recommendations of the majority of referees, and having discussed the matter further with referee 1 (who finds the wider structural analysis valuable for the field), we would like to invite you to submit a revised manuscript to EMBOJ.
Particularly important in revising your manuscript would be to address the concerns of referee 1 regarding the use of the Voss models. In addition, I would encourage you to follow the suggestion of referee 3 and to include Supplementary Figure 2 as a main figure in your paper (you are well inside our length limits here, so this is not a concern). Further discussion of the potential uncertainties as to register of the TM helices -as highlighted by referee 2 -would also be important.
I should add that it is EMBO Journal policy to allow only a single round of revision, and acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal _____ REFEREE REPORTS:
Referee #1 (Remarks to the Author):
Zhang et al. report a 4.4 Å cryo-EM density map of a laboratory vaccine strain Venezuelan equine encephalitis virus (VEEV). The cryo-EM density map contained strong electron densities of viral proteins E1, E2 and weak density of E3. From these electron densities, they put together full-length models of the VEEV proteins by combining atomic models from homologous Chikungunya virus (CHIKV) of the ectodomains (Voss et al., 2010) and de novo models of E1/E2 transmemberane helices. The latter transmembrane domains (endodomains) of E1 and E2 were missing in the Voss et al. models derived from crystallography. These models from the cryo-EM structure are very significant because they represent the full-length E1 and E2 proteins and are native structures as present in a full vaccine strain VEEV. VEEV has been developed into a biological weapon and is classified as an NIAID Category B priority pathogen. More significantly, no human vaccines or antiviral drugs thus far have been licensed and vaccine strain studied in this paper is one of the few experimental vaccines that have been used to protect laboratory workers and military personnel. Thus, a model of the virus, particularly those with atomic coordination information, would have great impact not only on understanding membrane virus structure, but also on efforts to engineer VEE for applications. The paper represents a significant pice of work in alphavirus research and should be of interest to the broad EMBOJ readership and likely also to the general public. I have two main concerns of the paper. First, although the paper is well written with great illustrations (typical of the Chiu lab), some important technical details are missing and should be provided in a revised manuscript (see below). The authors should describe how the sequence alignments were performed and how models from Voss were mutated and annealed with their de novo model of the endodomains. The authors repeatedly used C-alpha model to refer the structures in the text but some figures show labels of sidechain. This should be clarified. If atomic models were indeed built for E1, E2 and E3, the process should be described to inform the readers. Another major question relates to the use of the Voss model. After the Voss models of E3 and the ectodomains of E1, E2 were modeled for VEEV E1, E2 and E3, how much different were introduced to the original atomic model? Where were they? Given the approximately 55% (for E1) and 35% (for E2) sequence identities between VEEV and CHIKV, one would expect that their structures should be identical in most spaces. If they were indeed identical, the authors might want to simplify the long Result section of "E1 and E2 ectodomains" by simply stating this fact. Otherwise, the differences should be described to make the result more informative. Minor concerns: P4-5: specify "structural model". In addition, how were the VEEV models different from those of Voss et al. and Li et al. (2010) ? P6: Modeling of glycan. How big were the two putative glycan densities? Lower left corner of figure 2B shows a large region of density not modeled. What is it? P8: The E3 density was weaker and does not fit the model from Voss et al as well as those of E1 and E2. Was this a consequence of mixing pE2 and E3 structures? Figure 3C shows two of the four sample batches used in the cryo-EM structure contained pE2 and two did not. The authors should see if structure from sample batches 2 and 4 has stronger E3 density. How did the VEEV E3 model differ from the Voss model? P20: Sherman reference missing information. Figure 4 : The authors described the disappearance of side chain densities in the averaged structure, but which were nevertheless modeled as shown in figure 4C and 4D. This might reflect the existence of noise in the unaveraged map. In fact, the densities in figure 3C for W407 and W409 appear different from one another and they certainly are quite different from those expected from a good electron density map. The authors are cautioned in their registration of the C alpha positions. How were C terminal residues (E1 442 and E2 423) identified? Were they resolved in the averaged map? Figure 3D : the E3 model appears mostly outside the density. How is this model different from that from Voss et al.? Figure S2 : portion of endodomains were cut off. Figure S3 -4: how were these obtained?
Referee #2 (Remarks to the Author):
Chiu and colleagues describe a 3D cryoEM reconstruction of VEE at about 4.5 Å resolution (after averaging among quasi-equivalent locations). This is an elegant technical achievement, which goes beyond previous cryoEM work on alphaviruses in its level of interpretable detail. The parts of the structure that are clearly better resolved than hitherto are the transmembrane segments. Except for these bits, however, shown especially well in Fig. 4 , the model does not appear to reveal any critical structural features that one did not already understand from "hybrid" models based on crystal structures and lower resolution cryoEM reconstructions from Rosssmann, Kuhn, Rey, and others. This reviewer's suggestion is therefore that the MS might more usefully be rewritten as a shorter communication --e.g., for EMBO Reports --as EMBO J does not appear to do short-form publications. Should this be an option, then Figs. 1, 4 and perhaps part of 5 (although the presence of E3 isn't particularly exciting to anyone outside the alphavirus field) tell the story, while Figs. 2 and 3 do not add to existing alphavirus understanding. Potential uncertainties in the sequence register of the slightly kinked E1 TM helix (coloured reddish brown in Fig. 4A ,B) should be described more explicitly. That is, the model in which the GG sequence faces away from the E2 TM (rather than facing it at a close contact) needs more careful justification --presumably based on the register of W407 and W409. Are the main-chain locations to which the density bulges belong unambiguous? Is the GG motif conserved in other alphaviruses? What about other conservations --e.g., S417, which might cap the exposed NH at the apparent kink? In short, by focusing a shorter report on what is new, rather than struggling to extract significance out of less convincing (e.g., the hexamer-pentamer notion for capsid assembly) or less novel aspects, the authors would be highlighting the most significant novelties in their work, while better emphasizing the extent of their technical accomplishment.
Referee #3 (Remarks to the Author):
This manuscript describes the structure of the TC83 vaccine strain of VEEV as constructed from cryoEM images combined with information from the crystal structures of domains of other alphavirus proteins. As such, it provides a more complete picture of the structure of the alphavirus virion and the location of specific amino acids important for virulence and pathogenesis. The assembly of this structure provides useful insights into virion assembly and the induction of conformational change, fusion and uncoating associated with virion entry that will inform subsequent biologically motivated mutagenesis studies to test the authors' conclusions. Specific comments: 1. Some of the most interesting and useful information relevant to pathogenesis is contained in supplementary figure S2. Two paragraphs of the results are devoted to this figure and I would suggest that it be incorporated into the manuscript. 2. There is reference to supplementary figure S5 in the text, but I find no mention of S3 or S4, although these sequence alignments are useful. We would like to thank the editor and the reviewers for the very constructive comments. We have revised the text with all the suggestions made by the three reviewers. In particular, we have (1) added many technical details to clarify our model building procedure for the full length E1 and E2, including the use of the Voss model; (2) discussed the potential uncertainties as to the sequence registration of our models of TM helices raised by referee 2; (3) followed the suggestion of referee 3 and placed the supplementary Figure A1. To model the VEEV E1, E2 ectodomains and E3 (E1: residues 1-389, E2: residues 1-341, E3: residues 1-59), the sequence alignments and subsequent homology modeling ("mutation") was performed by MODELLER using Voss ' CHIKV model as the template. The missing parts in the crystal structure (E1: residues 390-442, E2: residues 342-423) were modeled de novo by tracing the backbones using GORGON and then converting the C-alpha models to all-atom models using the SABBAC online server. Finally, the homology and de novo models were stitched together in COOT to generate the full-length E1 and E2 atomic models, which were further refined by ROSETTA to produce our final models. The E3 homology model was not further refined by ROSETTA due to the less-resolved quality of our E3 density except the two apparent alpha-helices. We have added these technical details in the Methods part to clarify the steps in our model building process. The ROSETTA refinement uses the cryo-EM density map as a restraint, along with energy minimization to eliminate steric clashes and assure proper polypeptide geometry. In our 4.4 Å resolution cryo-EM map, a large portion of the side-chain densities (except for most of the bulky ones) are not fully resolved, which is expected at the current resolution. As a result, the side-chain conformations (rotamers) in our final model are not fully restrained by the cryo-EM densities and thus its accuracy is limited as any crystal structure determined at a similar resolution. In our manuscript, only the sidechains with evident protruding densities in the cryo-EM map are shown in the figures and discussed in the text.
Q2. Another major question relates to the use of the Voss model. After the Voss models of E3 and the ectodomains of E1, E2 were modeled for VEEV E1, E2 and E3, how much different were introduced to the original atomic model? Where were they? Given the approximately 55% (for E1) and 35% (for E2) sequence identities between VEEV and CHIKV, one would expect that their structures should be identical in most spaces. If they were indeed identical, the authors might want to simplify the long Result section of "E1 and E2 ectodomains" by simply stating this fact.
Otherwise, the differences should be described to make the result more informative.
A2. In response to this reviewer 's questions, we have simplified the description of the homology modeling process and added the content of structural comparison between our VEEV model and CHIKV/SINV crystal structure, along with two new Supplementary Figures, S2 and S3 . Although our VEEV model mostly agrees with the CHIKV crystal structure, our 4.4 Å resolution cryo-EM map has sufficient details to guide our model refinement to reveal the subtle differences between these two models. In the new Supplementary Figure S2 , we computed the root-meansquare-deviation (RMSD) per C-alpha atom for E1 and E2 ectodomains between our VEEV model and CHIKV model after being fitted to our averaged map. The results show that E2 ectodomain (residues 1-341) have more variations (RMSD 4.2 Å) than E1 ectodomain (residues 1-391) (RMSD 1.8 Å), with the largest variations mapped to not only the loop regions, but also some of the beta strands.
Minor concerns: Q3. P4-5: specify "structural model". In addition, how were the VEEV models different from those of Voss et al. and Li et al. (2010) ?
A3. We have changed the "structural model" to "all-atom model" which includes both C-alpha and side chain atoms. We have added the description of the structural comparison between our VEEV model and Voss ' crystal structure (PDB ID: 3N40) as described in our response to Q2. Furthermore, we have also used the same method to compute the RMSD between our VEEV model and Li 's SINV E1-E2 crystal structure at low pH (PDB ID: 3MUU, chain A), in which subdomain B of the E2 ectodomain is not resolved. Our results show an RMSD of 2.4 Å for E2 ectodomain and 2.9 Å for E1 ectodomain, with the most variations mapped to the E1 fusion loop region (please see our new Supplementary Figure S3 ).
Q4. P6: Modeling of glycan. How big were the two putative glycan densities?
A4. The placement of the atomic model of N-Acetyl-glucosamine (NAG) to the glycan densities (E1-N134 and E2-N318) suggests that either of the two glycan densities can accommodate only one monosaccharide rather than a disaccharide. We have modified Figure 2 to show the placement of one NAG to the corresponding glycan density in each case (please see the new Figure 2B and 2E). We did not include the glycans in our final model because we do not have enough resolution to determine their exact conformations.
Q5. Lower left corner of Figure 2B shows a large region of density not modeled. What is it?
A5. The density at the lower right corner of Figure 2B (now Figure 2C ) corresponds to E2. In this figure, there is also a yet-to-be-assigned small globular density (pointed by the blue dashed arrow), which was described in the text. To avoid confusion, we have revised this figure (now Figure 2C ) to show both E1 (magenta) and E2 (cyan) models. Figure 3C shows two of the four sample batches used in the cryo-EM structure contained pE2 and two did not. The authors should see if structure from sample batches 2 and 4 has stronger E3 density. How did the VEEV E3 model differ from the Voss model?
Q6. P8: The E3 density was weaker and does not fit the model from Voss et al. as well as those of E1 and E2. Was this a consequence of mixing pE2 and E3 structures?
A6. The weaker appearance of E3 density in our map may be attributed to three factors: (1) lower occupancy of E3 in the mature VEEV, as reflected by the SDS-PAGE result; (2) possible flexibility of the E3 N-terminal region or even the entire E3 molecule; (3) mixed conformations of pE2 and cleaved E3 are present in some of our samples. As suggested by this reviewer, we computed a separate reconstruction using only the 9,725 particles from sample batch 2, which does not contain pE2, and got a structure at 7.2 Å resolution. After subsequent averaging of the four subunits in one asymmetric unit (hereby call asymmetric unit averaged map or averaged map), we did not observe a better resolved E3 density as compared to the corresponding map from all the 37,315 particles. Combined with the fact that CHIKV E3 crystal structure in the E3-E2-E1 complex obtained by furin cleavage (PDB ID: 3N41) is very similar to that in the pE2-E1 complex (PDB ID: 3N40), except the furin loop, it seems unlikely that the weaker E3 density in our VEEV map is a consequence of mixing pE2 and E3 structure. Despite the good match of two rod-like densities outside the E1 and E2 densities with the two alphahelices of our E3 homology model, the E3 density appears less resolved than the rest of the density map, and some densities near the E3 N-terminal portion are missing. Consequently, we did not perform further refinement of our E3 homology model against the E3 density by ROSETTA. However, given the 52% sequence identity between VEEV E3 and CHIKV E3, we expect that the actual structure of VEEV E3 is very similar to our E3 homology model (C-alpha RMSD 0.3 Å with respect to the CHIKV template).
Q7. P20: Sherman reference missing information.
A7. The reference has been added to the text.
Q8. Figure 4: The authors described the disappearance of side chain densities in the averaged structure, but which were nevertheless modeled as shown in figure 4C and 4D. This might reflect the existence of noise in the unaveraged map. In fact, the densities in Figure 3C A8: Almost all of the bulky sidechain densities along the transmembrane (TM) helices remain visible before and after averaging, including E1-W407, E1-W409, E1-Y434 and E2-W387, although some of them appear less prominent than those in the unaveraged map. To clarify this point, we have revised the original Figure 3 (now Figure 5) to show the appearance of these bulky sidechains in the asymmetric unit averaged map instead of displaying the unaveraged map. These sidechain densities are sufficient to determine the registration of C-alpha positions for the E1, E2 TM helices.
After the initial placement of our TM helices models into cryo-EM density using GORGON, the positions of these C-alpha atoms were fine-tuned by the subsequent all-atom refinement using ROSETTA, which optimized the interface between these two TM helices. The C-alpha position of the E1 C-terminal residue E1-N442 can be identified by the abrupt ending of E1 TM helix density in the averaged map (please see our new Figure 5D and E), although its side-chain is not fully resolved. The E2 C-terminal residue E2-A423 is a small residue and is therefore not visible in the averaged map. However, there is evident side-chain density for its neighboring residue E2-R422 (please see new Figure 5D and E). As a result, the approximate Calpha position of the E2 C-terminal residue E2-A423 can also be identified confidently.
Q9. Figure 3D: the E3 model appears mostly outside the density. How is this model different from that from Voss et al.?
A9: Please see our response to Q6. Figure S2 : portion of endodomains were cut off. Figure S2 (now Figure 3 in the main text) to show the whole E1 and E2 models.
Q10.

A10. We have modified the Supplementary
Q11. Figure S3 -4: how were these obtained?
A11: The sequence alignments were performed by EMBL-EBI ClustalW2 online server (http://www.ebi.ac.uk/Tools/msa/clustalw2). We have added this information to the figure legend. A1: The density bulges in our asymmetric unit averaged map are distinct and are self-consistent in terms of the side-chain assignments. With these bulky sidechain densities (E2-W387, E1-W407, E1-W409 and E1-Y434) we can unambiguously determine the registration of C-alpha positions for the TM helices. Considering the register of W407 and W409, and assuming the helix keeps its winding path at the kink region, which is typically the case, the GG motif has to face away from the E2 TM helix. The GG motif is highly conserved in all the alphaviruses except for Ross River Virus (please see Supplementary Figure S5 ). This GG motif is different from the canonical GXXXG motif (with X being any residues) that is commonly found at the interface of interacting TM helices, where two glycines are brought to the same side of a helix, allowing close contact between the two helices. Combined with the fact that in our final model this GG motif is facing away from the E2 TM helix, it is unlikely that this GG motif is directly involved in the interaction between E1 and E2 TM helices. Instead, it may function to alleviate the steric forces at the inner-bending side of the kink. We have added the discussion for the sequence register at the kinked E1 TM helix into the text. In our final model, the closest contact between E1 and E2 TM helices exists between two small residues E1-S417 and E2-S381, presumably via hydrogen bond. Although residues at these two positions are not highly conserved, they vary among relatively small residues (Val, Leu, Ser, Thr and Ala) (please see the new Supplementary Figure S4 and S5).
Referee #3 (Remarks to the Author): Q1. Some of the most interesting and useful information relevant to pathogenesis is contained in Supplementary Figure S2 . Two paragraphs of the results are devoted to this figure and I would suggest that it be incorporated into the manuscript.
A1. This supplementary figure has become the Figure 3 in the main text. Figure S5 in the text, but I find no mention of S3 or S4, although these sequence alignments are useful. Figure S4 and S5) in the main text.
Q2. There is reference to Supplementary
A2. We have added references to Supplementary Figures about the sequence alignments of E2 and E1 (now supplementary
